Essen Biotech and Tavotek Biopharmaceutical Company of the United States established a R&D strategic alliance
-
Last Update: 2020-01-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Yisheng biopharmaceutical Co., Ltd and tavotek biopharmaceutical Co., Ltd of the United States jointly announced that they have reached a strategic R & D alliance to jointly develop a multi-target immunoanticancer drug combination based on ys-on-001 / 002 and tavo-301 / 303 Yisheng biopharmaceutical Co., Ltd is a multinational biopharmaceutical company integrating the R & D, production and sales of new immune biomacromolecule drugs and vaccine products; tavotek is an innovative biopharmaceutical company focusing on the development of new multi-specific antibodies, which are applied to tumors and autoimmune diseases The two sides also disclosed that they are negotiating new macromolecular biopharmaceutical cooperation projects outside the field of cancer.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
